Delivery Order SPE2DB22D2007-SPE2DB25FJ5KN
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of IMBRUVICA 140 mg capsules (90-count units) under a firm fixed-price contract with a ceiling value of $8,116.87. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of October 17, 2025. The vendor will perform the contract from its corporate headquarters in Conshohocken, Pennsylvania. IMBRUVICA is a specialized pharmaceutical product used in the...
- The Defense Logistics Agency awarded a delivery order valued at $16,233.74 to AmerisourceBergen Drug Corp for the supply of Imbruvica 140 mg capsules (90-count units) on September 3, 2025, with an ultimate completion date of September 24, 2025. This firm fixed-price, competitively awarded delivery order was placed without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract executed under...
- The Defense Logistics Agency awarded a delivery order valued at $7,575.75 to AmerisourceBergen Drug Corp for the supply of Imbruvica 420 mg tablets (28-count units) under a firm fixed-price contract. The order, issued on September 3, 2025, with an ultimate completion date of September 24, 2025, represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $8,116.87 to AmerisourceBergen Drug Corp for the supply of Imbruvica 140 mg capsules (90-count units) on April 22, 2025. This firm fixed-price, non-set-aside contract is scheduled for completion by May 13, 2025, with performance at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $48,701.22 to AmerisourceBergen Drug Corp for supply of Imbruvica 140 mg capsules (quantity: 90 units) with a completion date of October 10, 2025. This competitive award, issued on September 19, 2025, carries firm fixed pricing and contains no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a $15,151.52 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Imbruvica 280 mg tablets (28 count) on June 6, 2025, with completion targeted for June 30, 2025. This non-competitive, non-set-aside delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $1 billion through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $30,303.04 to AmerisourceBergen Drug Corp for 28 tablets of Imbruvica 420 mg on September 15, 2025, with completion targeted for October 6, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Imbruvica is a prescription medication used to treat certain blood cancers and lymphoid malignancies,...
- The Defense Logistics Agency awarded a $7,575.75 delivery order to AmerisourceBergen Drug Corp for IMBRUVICA 70 mg capsules (28-count) on August 28, 2025, with a completion date of September 19, 2025. This non-set-aside contract uses firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The pharmaceutical distributor, headquartered in...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,575.75 for IMBRUVICA 140 mg tablets (28-count supply) on August 28, 2025, with completion scheduled for September 19, 2025. This firm fixed-price, competitively awarded contract carries no set-aside designation and is being performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $7,575.75 delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Imbruvica 140 mg tablets (28-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation, scheduled for completion by September 15, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ5KNDelivery Order
The Defense Logistics Agency awarded a $48.7K firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Imbruvica 140 mg capsules (90-count units). The contract, which is not set-aside, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.9M through December 2026. Performance will be executed from the company's corporate headquarters in Conshohocken, Pennsylvania, with an ultimate completion date of October 20, 2025. Imbruvica is a critical oncology pharmaceutical used in the treatment of certain blood cancers, reflecting the federal government's need for specialized pharmaceutical supply through its medical procurement network. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, was selected through competitive procurement to fulfill this delivery order. The company serves as a key vendor for the Defense Health Agency and other federal healthcare systems, maintaining an extensive portfolio of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains. This delivery order exemplifies the operational efficiency of the DLA's pharmaceutical prime vendor model, which leverages standing contracts to expedite the procurement of critical medical commodities for military healthcare programs and other federal beneficiaries. The firm fixed-price structure and rapid completion timeline underscore the urgent nature of pharmaceutical supply chain management within federal healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $48.7k | 9/26/25 |